NuVasive Facility Expansion Triples Capacity; Stock Up 24% In January
This article was originally published in The Gray Sheet
Executive Summary
Spinal surgery system maker NuVasive's recently expanded production, training and warehousing capacity is spurring investor optimism that drove a 24.3% stock price increase in January to $12.7
You may also be interested in...
Gen-Probe Prepares For West Nile Virus Test Commercial Uptake
Gen-Probe expects an upsurge in revenue from its West Nile Virus blood screening assay shortly after FDA approval, according to CFO and VP-Finance Herm Rosenman
Gen-Probe Prepares For West Nile Virus Test Commercial Uptake
Gen-Probe expects an upsurge in revenue from its West Nile Virus blood screening assay shortly after FDA approval, according to CFO and VP-Finance Herm Rosenman
ANS “Ready” For Neuro-Stimulating Competition With Advanced Bionics
Advanced Neuromodulation Systems is girding for Boston Scientific subsidiary Advanced Bionics' full-scale launch of the Precision rechargeable spinal cord stimulator, expecting to be without a competing rechargeable system until 2005